These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11228405)

  • 1. In vivo tracking of tumor-specific T cells.
    Yee C; Riddell SR; Greenberg PD
    Curr Opin Immunol; 2001 Apr; 13(2):141-6. PubMed ID: 11228405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioma antigen.
    Toda M
    Adv Exp Med Biol; 2012; 746():77-84. PubMed ID: 22639160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell responses to cancer.
    Lee PP
    Methods Cell Biol; 2004; 75():513-32. PubMed ID: 15603440
    [No Abstract]   [Full Text] [Related]  

  • 4. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.
    Anichini A; Molla A; Mortarini R; Tragni G; Bersani I; Di Nicola M; Gianni AM; Pilotti S; Dunbar R; Cerundolo V; Parmiani G
    J Exp Med; 1999 Sep; 190(5):651-67. PubMed ID: 10477550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LiveCount Assay: concomitant measurement of cytolytic activity and phenotypic characterisation of CD8(+) T-cells by flow cytometry.
    Devêvre E; Romero P; Mahnke YD
    J Immunol Methods; 2006 Apr; 311(1-2):31-46. PubMed ID: 16527300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor antigens discovery: perspectives for cancer therapy.
    Wang RF
    Mol Med; 1997 Nov; 3(11):716-31. PubMed ID: 9407548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically modified tumour vaccines--where we are today.
    Nawrocki S; Mackiewicz A
    Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma vaccines: the paradox of T cell activation without clinical response.
    Nielsen MB; Marincola FM
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S62-6. PubMed ID: 10950150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
    Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
    Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cytotoxic T-lymphocytes and the recognition of tumor antigens--an approach to "preventive tumor vaccination?"].
    Peiper M; Goedegebuure PS; Eberlein TJ; Zornig C
    Zentralbl Chir; 1997; 122(3):141-8. PubMed ID: 9206906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of tumor-specific T lymphocytes with the ELISPOT assay.
    Schmittel A; Keilholz U; Thiel E; Scheibenbogen C
    J Immunother; 2000; 23(3):289-95. PubMed ID: 10838657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HLA-restricted cancer-specific killer T cells].
    Harada M; Itoh K
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():579-84. PubMed ID: 15861714
    [No Abstract]   [Full Text] [Related]  

  • 13. [Tumor antigen-specific cytotoxic T lymphocytes and cancer immunotherapy - review].
    Liu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Apr; 12(2):244-8. PubMed ID: 15157343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?
    Coulie PG
    Mol Med Today; 1997 Jun; 3(6):261-8. PubMed ID: 9211417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogene therapy.
    Lichtor T; Glick RP
    Adv Exp Med Biol; 2012; 746():151-65. PubMed ID: 22639166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
    J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DC-based cancer vaccines: lessons from clinical trials.
    Brody JD; Engleman EG
    Cytotherapy; 2004; 6(2):122-7. PubMed ID: 15203988
    [No Abstract]   [Full Text] [Related]  

  • 18. Generation of tumor-specific T-cell therapies.
    Morris E; Hart D; Gao L; Tsallios A; Xue SA; Stauss H
    Blood Rev; 2006 Mar; 20(2):61-9. PubMed ID: 15978709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic T cell responses against immunoglobulin in malignant and normal B cells: implications for tumor immunity and autoimmunity.
    Gricks CS; Gribben JG
    Curr Pharm Des; 2003; 9(23):1889-903. PubMed ID: 12871193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How much help does a vaccine-induced T-cell response need?
    Weber JS; Mulé JJ
    J Clin Invest; 2001 Mar; 107(5):553-4. PubMed ID: 11238555
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.